Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
Li W, Daoud SZ, Trivedi R, Lukka PB, Jimenez E, Molins E, Stewart C, Bharali P, Garcia-Gil E. Li W, et al. Among authors: daoud sz. Int J Chron Obstruct Pulmon Dis. 2023 Nov 27;18:2725-2735. doi: 10.2147/COPD.S434588. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 38046981 Free PMC article. Clinical Trial.
Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Sun Y, et al. Among authors: daoud sz. Respir Med. 2023 Nov;218:107393. doi: 10.1016/j.rmed.2023.107393. Epub 2023 Aug 26. Respir Med. 2023. PMID: 37640273 Free article. Clinical Trial.
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigí-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Hallas J, Pottegård A, Rebordosa C. Rivero-Ferrer E, et al. Among authors: daoud sz. Clin Drug Investig. 2022 Apr;42(4):319-331. doi: 10.1007/s40261-022-01120-2. Epub 2022 Mar 15. Clin Drug Investig. 2022. PMID: 35290649 Free PMC article.
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
Zhang H, Daoud SZ, Gillen MS, Calderon N, Heijer M, Molins E, Garcia-Gil E, Chen H, Li Q, Liu C, Ding Y. Zhang H, et al. Among authors: daoud sz. Drugs R D. 2022 Mar;22(1):35-42. doi: 10.1007/s40268-021-00374-z. Epub 2022 Feb 8. Drugs R D. 2022. PMID: 35133636 Free PMC article. Clinical Trial.
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.
Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E. Wise RA, et al. Among authors: daoud sz. Int J Chron Obstruct Pulmon Dis. 2021 Mar 18;16:689-699. doi: 10.2147/COPD.S285068. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33776428 Free PMC article. Clinical Trial.
Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.
Wise RA, Chapman KR, Scirica BM, Schoenfeld DA, Bhatt DL, Daoud SZ, Seoane B, Reisner C, Garcia Gil E. Wise RA, et al. Among authors: daoud sz. Chronic Obstr Pulm Dis. 2018 Jan 24;5(1):5-15. doi: 10.15326/jcopdf.5.1.2017.0149. Chronic Obstr Pulm Dis. 2018. PMID: 29629400 Free PMC article.